On 16 August, 2021, the UK Medicine and Healthcare products Regulatory Agency (MHRA) made Nuromol, a medicine that contains 200mg of ibuprofen and 500mg of paracetamol per tablet, available without the need to visit a pharmacy, providing an important new treatment option for temporary relief of mild to moderate pain. PEGUS was privileged to support label development and self-selection testing, and warmly congratulates the sponsor on this new GSL nonprescription product approval success.
This is the second fixed-dose combination pain reliever approval supported by PEGUS, and our third UK nonprescription approval success.
